Breaking: In surprise reversal, Sarepta says it will pause shipments of Duchenne gene therapy

Decision, which follows FDA request, means infusions nationwide will now be canceled

Log In    Subscribe BREAKING NEWS   In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy By Adam Feuerstein and Jason Mast Kristoffer Tripplaar/Sipa via AP Sarepta Therapeutics said Monday evening it will pause all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following a request by the Food and Drug Administration. It's a surprising reversal by the company, which had initially rejected the agency's request, issued Friday. Shipments will halt by close of business Tuesday evening. READ MORE Sign up for Daily Recap All the health and medical news you need today, in one email. Learn more. In Case You Missed It 1   Patient dies in Sarepta gene therapy trial, adding to safety concerns By Jason Mast 2   Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move By Jason Mast and Adam Feuerstein 3   After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry By Adam Feuerstein and Jason Mast 4   FDA rejects Capricor's cell therapy for Duchenne muscular dystrophy By Adam Feuerstein Don't miss out on another STAT investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us